Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology
Nanoform, an innovative drug particle engineering and nanotechnology company that provides novel API particle-size reduction services, is continuing its strategic growth through a significant €7 million investment, with Vator Securities acting as the sole bookrunner.